» Articles » PMID: 28353079

Biological Therapies in Otology

Overview
Journal HNO
Date 2017 Mar 30
PMID 28353079
Citations 2
Authors
Affiliations
Soon will be listed here.
Abstract

Hearing loss is present in millions of people worldwide. Current treatment for patients with severe to profound hearing loss consists of cochlear implantation. Providing the cochlear nerve is intact, patients generally benefit greatly from this intervention, frequently achieving significant improvements in speech comprehension. There are, however, some cases where current technology does not provide patients with adequate benefit. Ongoing research in cell transplantation and gene therapy promises to lead to new developments that will improve the function of cochlear implants. Translation of these experimental approaches is presently at an early stage. This review focuses on the application of biological therapies in severe hearing loss and discusses some of the barriers to translating basic scientific research into clinical reality. We emphasize the application of these novel therapies to cochlear implantation.

Citing Articles

Forgotten Fibrocytes: A Neglected, Supporting Cell Type of the Cochlea With the Potential to be an Alternative Therapeutic Target in Hearing Loss.

Furness D Front Cell Neurosci. 2019; 13:532.

PMID: 31866825 PMC: 6908467. DOI: 10.3389/fncel.2019.00532.


Pharmacokinetic principles in the inner ear: Influence of drug properties on intratympanic applications.

Salt A, Plontke S Hear Res. 2018; 368:28-40.

PMID: 29551306 PMC: 6133771. DOI: 10.1016/j.heares.2018.03.002.

References
1.
Kaiser O, Paasche G, Stover T, Ernst S, Lenarz T, Kral A . TGF-beta superfamily member activin A acts with BDNF and erythropoietin to improve survival of spiral ganglion neurons in vitro. Neuropharmacology. 2013; 75:416-25. DOI: 10.1016/j.neuropharm.2013.08.008. View

2.
Nemoto M, Koyama H, Nishiyama A, Shigematsu K, Miyata T, Watanabe T . Adequate Selection of a Therapeutic Site Enables Efficient Development of Collateral Vessels in Angiogenic Treatment With Bone Marrow Mononuclear Cells. J Am Heart Assoc. 2015; 4(9):e002287. PMC: 4599510. DOI: 10.1161/JAHA.115.002287. View

3.
Staecker H, Praetorius M, Baker K, Brough D . Vestibular hair cell regeneration and restoration of balance function induced by math1 gene transfer. Otol Neurotol. 2007; 28(2):223-31. DOI: 10.1097/MAO.0b013e31802b3225. View

4.
Staecker H, Praetorius M, Brough D . Development of gene therapy for inner ear disease: Using bilateral vestibular hypofunction as a vehicle for translational research. Hear Res. 2011; 276(1-2):44-51. PMC: 3109124. DOI: 10.1016/j.heares.2011.01.006. View

5.
Posel C, Moller K, Frohlich W, Schulz I, Boltze J, Wagner D . Density gradient centrifugation compromises bone marrow mononuclear cell yield. PLoS One. 2012; 7(12):e50293. PMC: 3516517. DOI: 10.1371/journal.pone.0050293. View